Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
With federal investigators bearing down on his committee, Rep. Tom Price, R-Ga., who is line to be secretary of the Department of Health and Human Services, showed little restraint in investing in health companies.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
President-elect Donald Trump’s Cabinet pick Tom Price “assisted” a company and campaign donor who tapped executives with an urgent request to donate.
Price and another influential GOP congressman got a discounted deal as an Australian firm seeking federal approval sought “sophisticated U.S. investors.”
Rep. Tom Price advocated on everything from a sperm test to a hot pepper ingredient on behalf of medical interests that included campaign donors.
While hundreds of his former patients submit claims for restitution, a Detroit cancer doctor convicted of making millions by purposefully poisoning them with drugs they didn’t need vows to prove his innocence.